nal Application No

PCT/EP2004/006567 A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K51/04 According to International Patent Classification (IPC) or to both national classification and IPC Minimum documentation searched (classification system followed by classification symbols) IPC 7 **A61K** Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, EMBASE, BIOSIS, PAJ, WPI Data, CANCERLIT, DISSERTATION ABS, CHEM ABS Data, BEILSTEIN Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Category 9 Relevant to claim No. X DEAN D C ET AL: "DEVELOPMENT OF A HIGH 1-10 SPECIFIC ACTIVITY SULFUR-35-LABELED SULFONAMIDE RADIOLIGAND THAT ALLOWED THE IDENTIFICATION OF A NEW GROWTH HORMONE SECRETAGOGUE RECEPTOR" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, ÚS, vol. 39, no. 9, 1996, pages 1767-1770, XP001018701 ISSN: 0022-2623 page 1768 -/--X Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance E. earlier document but published on or after the International filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but later than the priority date claimed in the art. *&* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 14 October 2004 11/11/2004 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Dullaart, A

ional Application No Pul/EP2004/006567

Category © Citation of document with indication with					
alegory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
K	JONES A N ET AL: "Synthesis, stability, and radiolytic decomposition of carbon-14 labeled MK0677" JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 38, no. 6, 1996, pages 561-565, XP008037025 GB ISSN: 0362-4803 page 562; figure page 564, paragraph SYNTHESIS - page 565	1-10			
	POMES A ET AL: "SOLUBILIZATION AND CHARACTERIZATION OF A GROWTH HORMONE SECRETAGOGUE RECEPTOR FROM PORCINE ANTERIOR PITUITARY MEMBRANES" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 225, 1996, pages 939-945, XP001019261 ISSN: 0006-291X abstract figures 1,3	1-10			
	WO 97/22367 A (PLOEG LEONARDUS V D; SCHAEFFER JAMES M (US); DEAN DENNIS C (US); SMIT) 26 June 1997 (1997-06-26) cited in the application the whole document	1-10			
	PONG S-S ET AL: "IDENTIFICATION OF A NEW G-PROTEIN-LINKED RECEPTOR FOR GROWTH HORMONE SECRETAGOGUES" MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 10, no. 1, 1996, pages 57-61, XP001018700 ISSN: 0888-8809 abstract page 58, left-hand column page 59, right-hand column; figure 3; table 1	1-10			
	-/				

Int inal Application No
Pur EP2004/006567

C.(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	Pur EP2004/006567
Category °	Citation of document, with indication, where appropriate, of the relevant passages	
	passages	Relevant to claim No.
X	NAGAMINE J ET AL: "Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686" JOURNAL OF ENDOCRINOLOGY, vol. 171, no. 3, December 2001 (2001-12), pages 481-489, XP002300844 ISSN: 0022-0795 abstract page 482, right-hand column, paragraph GHS-BINDING page 483, right-hand column, last paragraph - page 484, left-hand column, last line; figure 3	1-10
X	MATUSZEWSKI B K ET AL: "Determination of unlabeled and <14>C-radiolabeled drug candidates in biological fluids using LC-MS-MS - Issues and challenges" CHROMATOGRAPHIA 2000 GERMANY, vol. 52, no. SUPPL., 2000, pages S39-S45, XP008037024 ISSN: 0009-5893 the whole document	1-10
X	PATCHETT A A ET AL: "DESIGN AND BIOLOGICAL ACTIVITIES OF L-163,191 (MK-0677): A POTENT, ORALLY ACTIVE GROWTH HORMONE SECRETAGOGUE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, no. 15, 1 July 1995 (1995-07-01), pages 7001-7005, XP000651085 ISSN: 0027-8424 cited in the application the whole document	1-10

ational application No. PCT/EP2004/006567

Box II	Observations where contain alsima
	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 8-10 are directed to a diagnostic method practised on the human/animal body, a search has been carried out, based on the alleged effects of the compound/composition.
	Claims Nos.: 11-13 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
,	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
	national Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1.	as all required additional search fees were timely paid by the applicant, this international Search Report covers all learchable claims.
2. X A	as all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. A	is only some of the required additional search fees were timely paid by the applicant, this International Search Report overs only those claims for which fees were paid, specifically claims Nos.:
4. N	to required additional search fees were timely paid by the applicant. Consequently, this international Search Report is estricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark or	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 8-10 are directed to a diagnostic method practised on the human/animal body, a search has been carried out, based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 11-13

Claims 11-13 encompass a genus of compounds defined only by their function wherein the relationship between the structural features of the members of the genus and said function have not been defined. In the absence of such a relationship either disclosed in the as-filed application or which would have been recognized based upon information readily available to one skilled in the art, the skilled artisan would not know how to make and use compounds that lack structural definition. The fact that one could have assayed a compound of interest using the claimed assays does not overcome this defect since one would have no knowledge beforehand as to whether or not any given compound (other than those that might be particularly disclosed in an application) would fall within the scope of what is claimed. It would require undue experimentation (be an undue burden) to randomly screen undefined compounds for the claimed activity. Moreover, claim 13 does not contain any technical feature.

Therefore, no search has been performed for claims 11-13.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be

ormation on patent family members

Int Ial Application No
P-., -. 2004/006567

Patent document Publication Patent family Publication date Patent family Publication date Publication Patent family Publication P	Detect	1 - 1, -, 2004/00050/		
1 25 36 1337 WO 9/2236/ AI 26-06-1997	Patent document clted in search report			, application
	WO 9722367	A 26-06-1997	372230	20 00 1997

Form PCT/ISA/210 (patent family ennex) (January 2004)